Premature Tamoxifen Withdrawal Is Common in Male Patients With Breast Cancer
New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.
Outpatient Treatment Approved for Low-Risk Febrile Neutropenia
Outpatient management in patients with cancer who have a low risk of severe febrile neutropenia is an effective and safe option to standard inpatient treatment.
Navigation Program Shows Limited Benefit in Underserved, Urban Women With Breast Cancer
The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.
John Theurer Cancer Center at Hackensack University Medical Center: Providing Extraordinary Care to the Community
Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.
Breast Cancer is Diagnosed Later in Men but Is Less Often Fatal
New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.
Anastrozole Plus Fulvestrant Improved Survival in Metastatic Hormone Receptor-Positive Breast Cancer
The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.
Radiation Added to Hormone Therapy Bests Hormone Therapy Alone for High-Risk Prostate Cancer
Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.
Role of Bisphosphonate Therapy Refined but Still More Questions
The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.
Transplant Recipients Have Higher Risk of Diverse Cancers
Patients who receive a solid organ transplant have about twice the risk of developing cancer as the general population.
Targeted Therapies Yield Most Promising Results: A New Era in Melanoma Treatment Has Begun
Melanoma is one of the most frequent cancers; more than 2 million Americans are treated for skin cancer annually.
The Prostate Cancer Microenvironment: Implications for Therapy
In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.
Concurrent Zoledronic Acid Is Preferable in Letrozole-Treated Postmenopausal Patients With Breast Cancer
Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.
HPV and the Rise of Head and Neck Cancers
Human papillomavirus is perhaps best known as the main cause of cervical cancer, but if recent trends continue, by 2020 HPV will cause more cases of oropharyngeal cancer each year than cervical cancer.
Novel Therapeutics Have Revolutionized Multiple Myeloma Treatment
Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.
January 2012: Trials in Progress
The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.
Treatment of Large Cell Lymphoma: R-CHOP and Beyond
The treatment of diffuse large B-cell lymphoma continues to evolve, as researchers seek to improve upon the current standard of care.
Melanoma Breakthroughs Among Top 2011 Cancer Advances
Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.
Mouth Care Systems Alleviate Xerostomia After Radiotherapy
Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.
Much has been made of the difficulties companies, investigators, and patient advocates have in providing access to novel therapies.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512